Latest Insider Transactions at Allogene Therapeutics, Inc. (ALLO)
This section provides a real-time view of insider transactions for Allogene Therapeutics, Inc. (ALLO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Allogene Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Allogene Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2024
|
Deborah M. Messemer Director |
SELL
Open market or private sale
|
Direct |
9,136
-5.48%
|
$18,272
$2.18 P/Share
|
|
Dec 05
2024
|
Franz B Humer Director |
SELL
Open market or private sale
|
Direct |
9,221
-2.91%
|
$18,442
$2.16 P/Share
|
|
Oct 21
2024
|
Geoffrey M. Parker CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
36,404
-3.12%
|
$72,808
$2.84 P/Share
|
|
Aug 21
2024
|
Earl Martin Douglas SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
28,310
-5.93%
|
$56,620
$2.79 P/Share
|
|
Jun 18
2024
|
Deborah M. Messemer Director |
SELL
Open market or private sale
|
Direct |
18,641
-10.05%
|
$37,282
$2.28 P/Share
|
|
Jun 05
2024
|
Franz B Humer Director |
BUY
Grant, award, or other acquisition
|
Direct |
61,475
+16.25%
|
-
|
|
Jun 05
2024
|
Vicki L Sato |
BUY
Grant, award, or other acquisition
|
Direct |
61,475
+27.44%
|
-
|
|
Jun 05
2024
|
Deborah M. Messemer Director |
BUY
Grant, award, or other acquisition
|
Direct |
122,950
+39.87%
|
-
|
|
May 30
2024
|
Franz B Humer Director |
SELL
Open market or private sale
|
Direct |
11,200
-4.2%
|
$22,400
$2.34 P/Share
|
|
May 16
2024
|
Arie Belldegrun Director |
BUY
Open market or private purchase
|
Indirect |
1,724,137
+50.0%
|
$3,448,274
$2.9 P/Share
|
|
May 16
2024
|
Arie Belldegrun Director |
BUY
Grant, award, or other acquisition
|
Indirect |
344,828
+38.98%
|
$689,656
$2.9 P/Share
|
|
May 16
2024
|
David D Chang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
344,828
+6.69%
|
$689,656
$2.9 P/Share
|
|
May 16
2024
|
Geoffrey M. Parker CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
344,828
+22.85%
|
$689,656
$2.9 P/Share
|
|
Apr 22
2024
|
Timothy L. Moore Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,360
-6.14%
|
$52,080
$3.47 P/Share
|
|
Mar 14
2024
|
David D Chang President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
53,393
-1.18%
|
$213,572
$4.33 P/Share
|
|
Jan 30
2024
|
Geoffrey M. Parker CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
190
+0.02%
|
$570
$3.6 P/Share
|
|
Jan 25
2024
|
Timothy L. Moore Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,600
+25.46%
|
-
|
|
Jan 25
2024
|
David D Chang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
317,800
+6.58%
|
-
|
|
Jan 25
2024
|
Zachary Roberts EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
140,000
+21.37%
|
-
|
|
Jan 25
2024
|
Arie Belldegrun Director |
BUY
Grant, award, or other acquisition
|
Direct |
211,973
+10.2%
|
-
|
|
Jan 25
2024
|
Geoffrey M. Parker CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
29,400
+3.46%
|
-
|
|
Jan 25
2024
|
Earl Martin Douglas SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
41,800
+8.05%
|
-
|
|
Jan 22
2024
|
Zachary Roberts EVP of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
24,690
-6.17%
|
$74,070
$3.17 P/Share
|
|
Dec 18
2023
|
Deborah M. Messemer Director |
SELL
Open market or private sale
|
Direct |
18,640
-22.99%
|
$37,280
$2.7 P/Share
|
|
Oct 16
2023
|
Geoffrey M. Parker CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
790,000
+41.53%
|
-
|
|
Aug 14
2023
|
Earl Martin Douglas SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
435,834
+46.43%
|
-
|
|
Aug 10
2023
|
Yinlin Jack Chen SVP, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
11,401
+11.37%
|
-
|
|
Aug 07
2023
|
Stephen Mayo |
SELL
Open market or private sale
|
Direct |
10,000
-28.31%
|
$40,000
$4.29 P/Share
|
|
Jun 13
2023
|
Deborah M. Messemer Director |
BUY
Grant, award, or other acquisition
|
Direct |
74,561
+47.9%
|
-
|
|
Jun 13
2023
|
Owen N. Witte |
BUY
Grant, award, or other acquisition
|
Direct |
74,561
+20.29%
|
-
|
|
Jun 13
2023
|
Franz B Humer Director |
BUY
Grant, award, or other acquisition
|
Direct |
74,561
+21.86%
|
-
|
|
Jun 13
2023
|
Vicki L Sato |
BUY
Grant, award, or other acquisition
|
Direct |
59,649
+37.11%
|
-
|
|
Apr 24
2023
|
Timothy L. Moore Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
186,219
+50.0%
|
-
|
|
Apr 01
2023
|
Lillian Smith VP, Corporate Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
56,545
+28.71%
|
-
|
|
Mar 22
2023
|
Arie Belldegrun Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,282,976
+43.67%
|
-
|
|
Mar 22
2023
|
Zachary Roberts EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
148,035
+27.01%
|
-
|
|
Mar 22
2023
|
Eric Thomas Schmidt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
558,094
+39.29%
|
-
|
|
Mar 22
2023
|
Alison Moore Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
558,094
+45.34%
|
-
|
|
Mar 22
2023
|
David D Chang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,924,464
+31.45%
|
-
|
|
Mar 14
2023
|
David D Chang President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
22,340
-0.97%
|
$111,700
$5.56 P/Share
|
|
Mar 14
2023
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,879
-10.55%
|
$179,395
$5.47 P/Share
|
|
Mar 14
2023
|
Alison Moore Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,351
-6.79%
|
$41,755
$5.51 P/Share
|
|
Mar 14
2023
|
Veer Bhavnagri General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
23,628
-4.08%
|
$118,140
$5.67 P/Share
|
|
Feb 13
2023
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
3,000
-0.52%
|
$18,000
$6.85 P/Share
|
|
Jan 20
2023
|
Zachary Roberts EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
251,908
+50.0%
|
-
|
|
Jan 17
2023
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
3,000
-0.51%
|
$21,000
$7.04 P/Share
|
|
Dec 15
2022
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
5,602
-0.95%
|
$39,214
$7.53 P/Share
|
|
Oct 07
2022
|
Rafael Amado EVP of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
8,464
-1.54%
|
$93,104
$11.83 P/Share
|
|
Oct 07
2022
|
Rafael Amado EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
19,120
+3.36%
|
-
|
|
Oct 03
2022
|
Rafael Amado EVP of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
8,968
-1.66%
|
$98,648
$11.06 P/Share
|